Missouri Cannabis Legalization Takes Effect Today

Cannabis is now legal for adults in Missouri to consume and possess after the state’s voter-approved legalization law took effect today.

Legal sales remain off-limits for now but medical cannabis dispensaries in Missouri are expected to open their doors to anyone aged 21 or older sometime next year, possibly by February 2023. In the meantime, adults are now allowed to possess up to three ounces of cannabis. Additionally, adults can cultivate up to six flowering cannabis plants, six immature plants, and six plants under 14 inches at home for personal use.

John Mueller, the co-founder of Greenlight Dispensaries, told the Associated Press that dispensaries have started receiving calls from non-patients who are wondering if/when they can buy cannabis from the shops.

“I think everybody’s anxious and excited about adult use. Every dollar we sell is a dollar that doesn’t go to the black market.” — Mueller, via the AP

When recreational sales do launch next year, adult-use cannabis will be taxed at 6%. Officials predict the industry will generate more than $40 million in annual tax revenue for the state and at least $13.8 million per year for local governments.

Voters approved the state’s legalization law with 53% support during last month’s election, making Missouri the first Midwest state to adopt the reforms.

End


Lawmakers Pull Cannabis Banking From National Defense Bill

Congressional lawmakers have backed off from Democrats’ plan to include cannabis banking reforms in the National Defense Authorization Act (NDAA), Marijuana Moment reports.

The last-minute push to add the SAFE Plus package to the annual defense bill had drawn ire from the body’s Republican members. Sen. Kevin Cramer (R-ND), who co-sponsored the SAFE Banking Act in the Senate, said he felt that attaching the reforms to the NDAA “dilutes the proper role of this place.”

Senate Minority Leader Mitch McConnell (R-KY) said on the Senate floor:

“House and Senate Democrats are still obstructing efforts to close out the NDAA by trying to jam in unrelated items with no relationship whatsoever to defense. We’re talking about a grab bag of miscellaneous pet priorities — making our financial system more sympathetic to illegal drugs or the phony, partisan permitting reform and name-only language that’s already failed to pass the Senate earlier this year.” — McConnell, via Marijuana Moment

But Senate Majority Leader Chuck Schumer (D-NY) called the banking reforms a priority and suggested there could be another path forward. “This is something, again, that’s had bipartisan support. We’ve been working with Republicans. It’s a priority for me,” he said. “I’d like to get it done. We’ll try to discuss the best way to get it done.”

Lawmakers could still look to advance the reforms during the current lame duck session by attaching the so-called SAFE Plus package — which contains key language from the SAFE Banking Act, expungement language from the Harnessing Opportunities by Pursuing Expungement (HOPE) Act, and protections for gun-owning cannabis consumers via the Gun Rights And Marijuana Act (GRAM) Act — to a separate bill. Lawmakers may even attempt to pass the reforms as standalone legislation before the GOP takes control of the House next year, the report said.

End


Colombian Senate Votes to Legalize Cannabis

The Colombian Senate voted 56-3 in favor of advancing cannabis legalization reforms on Tuesday, bringing the South American country one step closer to ending cannabis prohibition outright, Marijuana Moment reports.

The bill was already approved in Colombia’s Chamber of Representatives in October but, because lawmakers are seeking legalization via a constitutional amendment, federal law requires the proposal to be subjected to eight legislative debates across two years before it can finally become law.

The proposed constitutional amendment speaks to the public health and economic benefits of ending cannabis prohibition and would give officials six months to establish rules for an adult-use cannabis market. But while the proposal largely liberalizes adult access to the plant, it would still limit cannabis possession and consumption near schools and in certain public spaces. The proposal also calls for public education campaigns about cannabis and would promote substance misuse treatment services, the report said.

Speaking in favor of the reforms at a Senate panel last month, Justice Minister Néstor Osuna said that Colombia was the victim of “a failed war that was designed 50 years ago and, due to absurd prohibitionism, has brought us a lot of blood, armed conflict, mafias, and crime,” according to the report.

Medical cannabis is already legal in Colombia — last year, lawmakers lifted a national ban on exporting dried cannabis flower and expanded the sale of medical cannabis products.

 

End


Minnesota Sues Company for Allegedly Selling High-Potency Cannabis Gummies

The Minnesota Board of Pharmacy has filed a civil lawsuit against Northland Vapor, alleging that the cannabis product retailer sold edibles that are 50 times more potent than legally allowed under the state’s limited adult-use program, CBS News reports.

The state pharmaceutical board and U.S. Food and Drug Administration (FDA) are together investigating complaints about Northland Vapor’s “Death By Gummy Bears” line of edibles. Officials raided the company’s Moorhead-based manufacturing warehouse and found nearly 150,000 packages of infused edibles exceeding the state’s 5-milligram cap on THC potency, according to the report.

The raids reportedly led to the seizure of:

  • 28,896 packages of “Death by Gummy Bears” edibles, containing 100 milligrams of THC per serving (totaling 2,500 milligrams per package)
  • 112,710 packages of “Death by Gummy Bears” edibles, containing 100 milligrams of THC per serving (totaling 2,500 milligrams per package)
  • 2,400 packages of “Wonky Weeds” edibles, containing 30 milligrams of THC per serving (totaling 300 milligrams per package)
  • 2,310 bottles of “Wonky Weeds” syrup containing 700 milligrams of THC per bottle

Tyler Leverington, an attorney for Northland Vapor, said the state’s lawsuit was an “aggressive tactic” aimed at smearing the company’s reputation.

“There is no evidence of any harm arising from the proper use of Northland products. The state’s effort to suggest otherwise are shameful,” Leverington told CBS News. “Northland is a small business committed to making a quality product and now must fight for its life against over-zealous regulators in St. Paul looking to make a splash with their newly adopted law.”

While the 2018 Farm Bill federally legalized hemp and all of its derivatives, FDA has previously noted that products containing hemp-derived delta-8 THC “have not been evaluated or approved by the FDA for safe use in any context.”

Minnesota’s unique cannabis edibles law took effect on July 4, legalizing gummies and similar products that contain no more than 5 milligrams of hemp-derived THC (including both delta-8 and delta-9 THC) for adults aged 21 and older.

End


Jointly Announces ‘Matches’ Cannabis Retail Sales Software

Jointly Matches Empowers Budtenders with Goal-Specific Product Insights

Jointly, the cannabis discovery company, today announced the launch of Jointly Matches, a first-of-its-kind, goal-based, data-driven cannabis shopping cart builder for the modern cannabis retailer.

This new software promises to increase revenue for retailers and make budtender training easier, all while helping retailers connect their customers with the best performing products for their goals.

“The work of the budtender is complex and multifaceted. Jointly Matches is here to make it easier. Budtenders are expected to be therapists, psychologists, pharmacists, educators, merchandisers, plant biologists, and guides to the consumer. All while being effective retail salespeople,” explains David Kooi, Jointly’s Co-Founder and CEO.

Cannabis is a complex plant that produces a variety of effects. The modern cannabis retailer often sells more than a thousand different products, each with unique characteristics.

“With Jointly Matches, retailers can empower their budtenders with goal-specific product performance insights. Insights packaged in an intuitive cart-builder, built so they can sell more cannabis to more people, more easily, and for all the great reasons why people consume,” continues Kooi.

Using Jointly Matches, a budtender engages in a focused conversation about a customer’s purpose and intention. Guided by the 12 goals that comprehensively cover the reasons why people shop for cannabis, they select from:

Relax & refresh, Relieve everyday stress, Improve sleep, Energize & uplift, Ease everyday pain, Enjoy social experiences, Focus, Create, Exercise, Stimulate appetite, Enhance intimacy, Exercise recovery.

“Utilizing our unique goal-specific product performance data, Jointly Matches recommends products that are best at providing the experience that people want,” explains Kooi.

The recommendations are powered by Jointly’s mobile app, where hundreds of thousands of cannabis enthusiasts reflect on their cannabis experiences and rate products for effectiveness, flavor, and aroma.

Jointly’s product matching algorithm considers product ratings, the customer’s goal, product type, cannabinoid content, strain, and more. No brand, grower, or manufacturer can pay for better ratings or to be a better match.

Retail owners, managers, and budtenders can view a demonstration of Jointly Matches here.

“Using Matches, retailers can send their customers home confident in their purchases – and ready for a good experience. We look forward to working with retailers to usher in a new era of purposeful cannabis consumption,” adds Eric Gutshall, Jointly’s Co-Founder and Chief Development Officer.

About Jointly

Jointly is the cannabis discovery company. Powered by a proprietary data platform, the company was created on the premise that purposeful cannabis consumption is the key to unlocking a better you. It has the industry’s first – and only – experience-based app for purposeful cannabis consumption.

Cannabis enthusiasts use the platform to discover new products and reflect on their experiences to reveal insights that help them reach their goals. Their authentic, unbiased experiences power Jointly’s trusted, goal-specific product recommendation engine.

For additional information, visit jointlybetter.com and download the app for free on Apple / Google.

End


Senate Proposal Would Prepare for Federal Cannabis Legalization

Sen. John Hickenlooper (D-CO) introduced legislation last week seeking to prepare the U.S. for the seemingly inevitable end of cannabis prohibition. Dope Magazine reports that the proposal — the Preparing Regulators Effectively for a Post-Prohibition Adult Use Regulated Environment (PREPARE) Act — would direct the U.S. attorney general to develop a framework for federally regulating the cannabis industry.

Hickenlooper was Colorado‘s governor when it made history as the first state to pass and adopt cannabis legalization reforms.

“A decade after Colorado pioneered marijuana legalization, Americans overwhelmingly support the same at the federal level. This bipartisan, bicameral framework, based on Colorado’s Amendment 64 Task Force, will replicate our success nationally.” — Hickenlooper, in a statement

If approved, the PREPARE Act would task the attorney general with creating a 24-member “Commission on the Federal Regulation of Cannabis” that would devise a federal cannabis plan based on existing federal and state alcohol regulations. The commission, without any actual rulemaking authority, would have one year following the bill’s passage to present its regulatory plan to Congress and the plan would need to account for each state’s unique cannabis industry and laws.

The bill’s companion bill in the House is sponsored by Rep. Dave Joyce (R-OH), who said he was “thrilled” to see the bill introduced in the Senate as well, “making it not only further bipartisan, but bicameral, and bringing it one step closer to becoming law.

“This legislation gives lawmakers on both sides of the aisle the answers they need to effectively engage on cannabis reform, safely and effectively regulate it, and remedy the harms caused by the failed war on cannabis,” Joyce said in a statement.

End


New Jersey Regulators Approve Cannabis Consumption Lounge Rules

The New Jersey Cannabis Regulatory Commission (NJ-CRC) last week approved its proposed ruleset for cannabis consumption lounges in the state, the New Jersey Monitor reports.

The proposed rules would allow for indoor or outdoor enclosed consumption lounges at any licensed cannabis retailer. Consumption lounges in the state will need to be approved by the NJ-CRC directly as well as local authorities. Lounge employees will be required to provide safe environments for people to consume cannabis and workers would be prohibited from “overselling” to consumers, the report said. Additionally, like the state’s retail rules, patrons of the consumption lounges will be required to show photo ID demonstrating they are at least 21 years old.

The state’s cannabis regulators voted unanimously to approve the rules, which next will enter a 60-day public comment period before officials can reconsider and finalize the regulations.

“I truly believe that this rule proposal, like everything else we’ve tried to do, adequately balances both equity and safety and will open up new opportunities for businesses and consumers.” — Jeff Brown, NJ-CRC’s Executive Director, via the Monitor

The proposed rules carry a $1,000 application fee for all applicants but, if approved, microbusinesses will face a $1,000 licensing fee while a standard consumption lounge business license would cost $5,000, the report said.

Cannabis sales launched in New Jersey earlier this year on April 21 after Gov. Phil Murphy signed the state’s legalization law in February.

End


Fewer Than 250 Pennsylvanians Qualify for Cannabis Pardons

While thousands had applied for the cannabis pardons announced by Pennsylvania Gov. Tom Wolf (D) earlier this year, fewer than 250 people have actually qualified and will get to clear their records, PennLive reports.

The state said that more than 3,500 applications for cannabis clemency were received but following a vote on Thursday by the Pennsylvania Board of Pardons, just 231 cases were set to advance for a final vote before the board on December 16. Any cases which pass that final round of consideration will then go to Gov. Wolf for pardoning.

According to the report, 2,002 applications were rejected for not meeting the requirements of the mass pardoning project while another 434 applications were held for further consideration at a later point.

The program was announced on September 1 and applicants had until September 30 to apply for clemency. That short timeframe — coupled with a requirement for applicants to have been convicted of simple cannabis possession but otherwise hold a perfectly clean criminal record — is likely limiting the number of people who can qualify for the program.

“Often cannabis consumers get multiple convictions when they are arrested that first time. They get a paraphernalia charge, and they get a possession charge all at once. You would have to essentially lead a police-free life other than that one marijuana encounter to qualify.” — Chris Goldstein, NORML’s New Jersey regional organizer, via PennLive

Pennsylvania‘s cannabis pardoning project was announced weeks before President Joe Biden (D) issued pardons for all federal cannabis possession charges and called on governors around the U.S. to follow suit.

End


How Cannabis Companies Should Approach DEI

Editor’s note: This editorial was contributed by Melanie Davis, Chief Operating Officer of The People’s Ecosystem, a California-based and equity-focused multistate cannabis operator.

It’s often said that Diversity, Equity, and Inclusion (DEI) Initiatives are not profit-focused but I’d argue that that’s mostly because they are not looked at as a long-term investment. Instead, they’re looked at as an “issue” — we are looked at as “issues,” rather than as vertical support and an economic engine of your corporate ecosystem. Additionally, the return on investment of DEI is rarely measured accurately, if it’s measured at all, and in most cases, senior decision-makers are insulated from these initiatives, programs, and/or policies, deflating their importance and sustainability.

For two and a half decades, I have seen people with good intentions confuse that with effective actions and tangible results. But the good news is that as an industry, we are in our infancy. Together, we are building the cannabis industry day by day, in real-time, and we are uniquely positioned to build from the ground up and diversify right out of the gate! It’s not like we are having to deconstruct businesses that have been around since the industrial revolution. The opportunity to do it right, and make it right, is here and now.

DEI as a P&L responsibility

A diverse company increases productivity and profitability. It reduces absenteeism and attrition, and it improves talent acquisition and retention. With intentional diversity, equity, and inclusion initiatives (plural), one could absolutely expect an increase in innovation and innovation-related profits.

Let’s expand on the financial benefits of well-developed and intentional DEI initiatives:

McKinsey found that ethnically diverse executive teams are 36% more likely to see top financial performance, while Boston Consulting Group determined that companies with above-average leadership diversity generated innovation-related revenue 19% higher than companies with below-average leadership diversity. As an example, our company dropped 57 product SKUs in less time and with less money than it takes to launch one, and I work for one of the few BIPOC women-led MSOs in the space. Imagine those returns — they significantly add up.

McKinsey/Boston Consulting Group also found that companies like The People’s Ecosystem are 83% more likely to be able to recruit millennials, and that’s important because over 44% of millennials look like me and are a bridge to Gen Z, where over 50% of that market share identifies as BIPOC. Let me say that again: over 50% of Generation Z are Black, Indigenous, and People of Color and, get this, they all have a supercomputer in their pocket where they can instantly know all about you, your company, and if it aligns with their values.

This generation knows the harm the racist war on drugs caused their parents and grandparents, that they were likely displaced due to predatory housing lending practices, and the overwhelming impact that displacement has had on overall health, all revealed to the masses during the global pandemic. These potential consumers keep their receipts — they are archived and shared in the form of screenshots, memes, and PDFs. That is why if you are responsible for your company’s bottom line, you must have effective internal DEI initiatives that are directly tied to your Profit & Loss Statement (P&L).

What does your P&L say about DEI?

An income statement tells you two things: it summarizes revenue, costs, and expenses incurred during a specific period, usually a fiscal quarter or year, and it also provides information about a company’s ability or inability to generate profit by increasing revenue, reducing cost, or both. That is textbook.

For reasons stated earlier regarding a certain 19% bump in innovation-related revenue for companies with diverse leadership, here is how I read an income statement: I count all Diversity, Equity, and Inclusion as assets, and everything else as a liability. Why? Because failure to diversify will choke your company out of the market.

Remember, over 50% of Gen Z look like me. People get freaked out when I say that but keep in mind the number one financial rule to achieve revenue goals and protect your company from volatility is diversification. ¡Hola!

Liabilities

Again, I count everything else as liabilities: that includes revenue, cost of goods sold, sales and marketing, employee-related expenses, operating income, and, of course, time. The rule of diversification tells me that if DEI is not tied to any of these line items, then they are a liability and will cost you.

There are many areas we can look at but let’s dive right into some of my favorites on the P&L.

Sales and marketing

You should always have a diverse sales force that is reflective of your DEI values both internally and externally, and from the top down. If you truly have that, and it is financially supported, then your advertising investments will also have authentic representation which will lead to success.

Having first-hand experience with this for two and a half decades in the media industry, I can tell you what happens when businesses fail to invest in this adequately. As a former publisher of diverse newspapers and magazines, I would often embark on a journey with a newly hired marketing person of color whose intentions were to expand and diversify their company’s market share. We would collaborate and build a successful campaign that would ultimately be short-lived. But not because the advertising didn’t work — the numbers don’t lie — but rather because their superior(s), who had been insulated from the corporate DEI initiatives, would be romanced by mainstream media implying that they too could reach our same target audiences. As one could imagine, our ad campaign would get pulled and go to a mainstream media outlet(s) and at the end of the day, the target audience was last, as were the future capital returns on investment. That’s a DEI fail.

Employee expenses

Next, let’s address employee-related expenses. Of course, this is where workers compensation, insurance, and similar concerns are considered, but this is also where we can see how diversity is supported among your company’s C-suite, your part-time employees, and even contractors.

When broken down, one can discover trends in corporate culture. I recommend looking deeper at expense accounts, especially those of your senior leadership. Do these expenses foster “dude culture” or diverse culture? For most companies, this will be the largest expense category on their statement, and it directly relates to profitability. These expenses can either be counted as an asset or a liability toward diversity, equity, and inclusion. If your company currently fosters a “dude culture,” in order to rectify this, start with building an expense policy that encourages local diverse engagements. Corporate expenses should be hyper-local with diverse businesses: get rid of anything toxic because it just doesn’t add to the bottom line and could pose significant liabilities.

Operating income

Now let’s talk about operating income. Net operating income is one of the most important lines on the P&L statement because it shows what’s left over after all your expenses are paid. If the number is positive, it means your business is profitable. If it’s negative, it means that your business is spending more than it brings in and you’re burning capital just to stay in business, which is normal for companies like startups, of course, but even if you expect to operate at a loss, you will still want to keep an eye on this to track how much you’re burning and what you are leveraging. There are many opportunities that could be leveraged in this category, from your facility(s) locations to vendor diversity. And if you can’t identify diversity within your vendor supply chain, then help invest in diverse people who want to build that business.

The numbers don’t lie

The P&L is a crucial tool in managing your business’s money, and knowing how to read one through the lens of diversity, equity, and inclusion will be vital for getting the information you need to run your company for long-term success. With a solid grasp of how your company is trending and which areas to focus on, you’ll be able to make more accurate financial projections and partnerships, and will better recognize the return on investment for your DEI initiatives — again, plural — and how that investment across the board directly impacts your P&L.

I am going to remind you one last time that by vesting your interest in diversification, not only are you helping repair the harm caused by the war on drugs but your company will be rewarded with increased innovation-related profits, and you should be prepared for a very diverse future.

End


Top Democrats Plan Cannabis Banking Push for Lame Duck Congress

Bipartisan efforts in the lame-duck Senate are working to close out the year with significant cannabis banking reforms, Axios reports.

Headed by Senate Majority Leader Chuch Schumer (D-NY), the effort looks to combine two cannabis reform bills — the Secure and Fair Enforcement (SAFE) Banking Act and the Harnessing Opportunities by Pursuing Expungement (HOPE) Act — and attach them to one of the year-end “must-pass” bills like the annual National Defense Authorization Act. If successful, it would be the second-ever cannabis reforms bill approved at the federal level after lawmakers passed improvements to the cannabis research process earlier this year.

As it originated, the SAFE Banking Act would allow cannabis businesses in state-legal markets to open bank accounts and acquire loans. Meanwhile, the HOPE Act would establish a Department of Justice (DOJ) grant program to help states and local governments expunge cannabis convictions.

Cannabis banking access is a popular, bipartisan issue among both elected officials and American voters but this would be the first time the Senate considers a proposal to normalize the industry’s access to financial services. The House has passed the SAFE Banking Act seven times previously but each time it ultimately failed to gain traction in the Senate.

Before Sen. Schumer would commit to the proposal, DOJ reportedly confirmed to the majority leader that the agency would be able to implement the reforms. Schumer had introduced his own cannabis reforms bill earlier this year — the Cannabis Administration and Opportunity Act — which sought to federally legalize cannabis and establish a national social equity program.

Meanwhile, President Biden signed into law the country’s first-ever stand-alone cannabis reforms bill last week, streamlining researchers’ ability to investigate the plant’s medicinal properties.

End


President Biden Signs Historic Cannabis Research Bill

President Joe Biden (D) signed the nation’s first-ever standalone cannabis reforms bill on Friday, paving the way for researchers to more easily investigate the medicinal properties of cannabis, Marijuana Moment reports.

The Medical Marijuana and Cannabidiol Research Expansion Act originated in the House, sponsored by Reps. Earl Blumenauer (D-OR) and Andy Harris (R-MD), where it was passed in July with bipartisan support. The Senate version of the bill, sponsored by Sen. Dianne Feinstein (D-CA), was formally approved by lawmakers last month.

Under the new law, the U.S. attorney general will have 60 days to either approve a cannabis research application or request additional information from the applicant. The law also increases efficiencies for researchers who request larger quantities of cannabis, the report said.

The Congressional Cannabis Caucus released a joint statement from its co-chairs, which include Blumenauer and fellow Reps. Dave Joyce (R-OH), Barbara Lee (D-CA), and Brian Mast (R-FL):

“For decades, the federal government has stood in the way of science and progress — peddling a misguided and discriminatory approach to cannabis. Today marks a monumental step in remedying our federal cannabis laws. The Medical Marijuana and Cannabidiol Research Expansion Act will make it easier to study the impacts and potential of cannabis.” — Congressional Cannabis Caucus statement, via Marijuana Moment

The White House also released a statement thanking the lawmakers who spearheaded the effort: “Thank you to Representatives Blumenauer, Harris, Griffith, Joyce, Mace, and Perlmutter, Delegate Norton, and Senators Feinstein, Grassley, Schatz, Durbin, Klobuchar, Tillis, Kaine, Ernst, Tester, and Murkowski for their leadership,” the news release said.

The Biden Administration had previously signaled the president’s intent to sign the historic bill.

End


Colorado Cannabis Industry Adopts ‘Use-By’ Labeling Requirements

Officials with Colorado’s Marijuana Enforcement Division (MED) have approved new rules for the state cannabis industry, including new “use-by” labeling requirements for cannabis products, according to a Cannabis Business Times report.

The regulations package, approved on December 1, also carries rules allowing for medical cannabis to be redesignated for circulation in the adult-use marketplace. The redesignation rule will take effect next month on January 1, 2023, while the new “use-by” package labeling requirements — which also includes new demands for cannabis product storage conditions — will take effect one year later, on January 1, 2024.

“Beginning January 1, 2024, all regulated marijuana products must be labeled with a use-by date and storage conditions prior to sale to a patient or
consumer. Licensees are encouraged to conduct shelf-stability testing to establish appropriate use-by dates for products, however, if a Licensee chooses not to conduct testing, a 9-month use-by date will apply.” — MED news release excerpt

The new regulations follow months of “extensive” engagement between MED representatives and cannabis industry stakeholders, according to the report.

“As in previous years, the MED tackled significant topics during this year’s rulemaking session. While much of the MED’s rulemaking is legislatively driven, we appreciate how the MED’s rulemaking design provides opportunities to hear from and collaborate with our diverse set of stakeholders,” MED Senior Director Dominique Mendiola said in a statement. “The significant contributions of our team and members of the public have been critical to informing both regulatory updates and improvements to existing rules and processes.”

The rules package also extends Colorado‘s cannabis social equity designations, addresses license transfers for cannabis delivery companies, boosts worker safety considerations, adds new security requirements amid an increase in cannabis industry burglaries, and more.

End


A Golden State Live Rosin Vaporizer Review

A Golden State (AGS), the premium California luxury cannabis brand, has added a line of live Rosin solventless vapes to its menu of offerings. With more strains coming soon, the selection features proprietary cultivars like Wood, Caramel Apple, and Snow Dream.

Using only indoor flower grown with cocoa and watered with mineral-rich mountain run-off from Mt. Shasta in Northern California, the mature flower products at AGS are picked at peak potency and frozen within 30 minutes to preserve each strain’s natural cannabinoid, terpene, and flavor profiles. Then, the live rosin is extracted using only water, pressure, and heat, thereby creating a full spectrum live rosin, which enriches the entourage effect.

The caramel apple AGS vape pen I had the opportunity to review was a new experience in vaping for me. The care put into the plants and the extraction methods really came through in the vapor quality. The caramel apple strain has a fruity taste, which happens to be my favorite terpene profile, but with a note of diesel coming through on the gentle exhale. The effects came on slowly with a very noticeable entourage effect eventually settling in with a relaxing, yet strong heady high.

The easy-to-use pen features a tailor-made made battery that gives the vapor a consistent smooth feel and flavor with every pull. The heating coils are encased in ceramic and each pen is rechargeable to avoid any unused product left behind in the cartridge.

When I was enjoying the AGS vape pen, the battery worked perfectly, providing a smooth tasty hit each time with no coughing. The rechargeable feature gave me comfort in knowing that the AGS live rosin on the inside would not go to waste. For me, as a vegan, an added bonus was the limited edition vegan leather carrying case that adds a level of discreetness and style while using the device, fitting easily in your pocket or purse.

Thanks to AGS for the great product — the care and ingenuity that went into each pen really came through from the time I opened the packaging to the vapor quality I experienced while sipping on the pen.

The live rosin vape can be found in select California dispensaries and you can learn more about A Golden State and its other selections at its website.

End


Report: Legal Cannabis Is Eating Into Alcohol Sales

Analysts at Cowen Equity Research report that legal cannabis sales in the U.S. have begun to eat into the sales of beer, wine, and liquor although the alcohol industry is far from being crippled, according to a MarketWatch report.

The researchers said they referenced about 20 years of government surveys and spending data, and an analysis of more than 8 million survey responses, including results from Nielsen and the Cowen Consumer Survey, to investigate the effects of cannabis on alcohol purchases.

Cowen Equity Research analyst Vivien Azer said in the report that the cannabis industry’s near-term impact on alcohol sales is mostly manageable but Azer noted the legal cannabis market has now grown to about 10% the size of the alcohol market — that’s a five-fold increase from the 2% of the alcohol market that cannabis amounted to just five years ago.

“Cannabis should gain [four times] the number of consumers as alcohol [will gain] over the next five years … as younger consumers also take longer breaks from alcohol.” — Azer, via MarketWatch

Cowen Equity Research’s own survey also revealed that 60% of cannabis consumers report having cut back on their alcohol consumption.

Research from the Journal of Adolescent Health published earlier this year found that the 2012 legalization of adult-use cannabis in Washington did not lead to increased alcohol and cigarette use in the Evergreen State.

 

End


Berkeley Officials Advance Psychedelics Decriminalization Resolution 

City officials in Berkeley, California have advanced a proposal to decriminalize psychedelics, Marijuana Moment reports. The Berkeley Community Health Commission passed the measure unanimously on Tuesday and the resolution now moves to the City Council for consideration.

In a break from other decriminalization proposals around the U.S., the Berkeley measure would apply to some synthetic psychedelics including LSD but not naturally occurring entheogenic substances like peyote or ibogaine.

But while the resolution would decriminalize simple possession, advocates who originally pushed for the reforms oppose certain parts of the resolution, the report said — namely, the omission of language deprioritizing law enforcement efforts against the gifting and sharing of psychedelics among adults. City officials noted that they had removed language to that effect so as to avoid nurturing an unregulated, gray market for psychedelics:

“In these gray markets, we see enterprising entrepreneurs opening commercial operations such as delivery services (advertised with fliers and posters), storefront dispensaries, pop-ups, and outdoor market booths, sometimes asking for ‘suggested donations,’ and sometimes not bothering at all with the pretense that they are merely ‘giving away’ the substances.” — Berkeley Community Health Commission report excerpt

The California state Senate advanced a bill earlier this year to legalize the possession of psychedelics but the General Assembly ultimately gutted the proposal and its sponsor pulled the bill, promising to try again next year.

Meanwhile, woters in Oregon opted to decriminalize psychedelic mushrooms and establish a medicinal industry in 2020. And just last month, Colorado passed its own statewide legalization measure for psychedelic mushrooms.

End


Curaleaf Cuts Staff Amid Cannabis Industry Downturn

The cannabis giant Curaleaf laid off approximately 220 employees last week heading into the Thanksgiving holiday, Insider reports. Curaleaf, which employs more than 6,000 people, is a vertically integrated multistate operator that grows and sells cannabis through its own storefronts in 21 states including Arizona, Florida, Michigan, and Illinois.

A Curaleaf representative told Insider the cuts were “part of an effort to control costs and drive efficiencies in the face of economic uncertainties ahead” but declined to specify which company departments were the most heavily affected.

“I don’t like having to deliver this news, and we haven’t reached this decision easily,” CEO Matt Darin said in a company-wide email.

“The cannabis industry has grown fast and is constantly evolving. In the current environment with inflationary pressures, increased competition, and slowing growth, it’s incumbent on us to be more efficient.” — Excerpt from Darin’s email announcing the layoffs

The company is now in discussions with unionized employees at affected locations, Darin said in the Insider report.

Curaleaf’s latest layoffs come after 50 jobs were cut and a company facility in Sacramento, California was shuttered in October. Other cannabis industry giants have likewise experienced job cuts this year amid rising inflation and economic uncertainty from years of pandemic restrictions and Russia’s unprecedented invasion of Ukraine, including major cannabis tech companies like Eaze, Dutchie, and Weedmaps (which laid off 10% of its workforce in August amid a California sales slowdown).

End


Rhode Island Launches Adult-Use Cannabis Sales

Adult-use cannabis sales officially launched in Rhode Island today, December 1, with the industry’s first customers lining up at licensed dispensaries in anticipation, WJAR reports.

The sales launch comes just over a week after regulators awarded hybrid retail licenses to five of the state’s six medical cannabis “compassion centers,” giving them the go-ahead for adult-use sales.

“There should be a lot of economic injection that should come out of this as sales really start to roll through a much more regulated market. We think there should be tons of opportunities for everyone within the state.” — Anthony Georgiadis, CFO of Green Thumb Industries, via WJAR

The Department of Business Regulation said Rhode Island had moved faster than any other New England state in adopting and implementing its adult-use reforms, according to the report.

The state’s top cannabis regulator, Matt Santacroce, said his office is hiring new staff and plans to triple its cannabis inspection abilities.

Rhode Island was the 19th U.S. state to adopt significant cannabis reforms after lawmakers passed the state’s legalization bill earlier this year. Under the measure, adults 21 and older can purchase and possess up to an ounce of cannabis, keep up to 10 ounces at home for personal use, and home-grow up to six (three mature, three immature) cannabis plants.

End


Cannabis From New York’s Unlicensed Shops Tests Positive for E. Coli, Salmonella

According to a recent investigation, about 40% of cannabis products bought from unlicensed cannabis shops in New York City tested positive for harmful contaminants including E. coli, lead, and salmonella, Bloomberg reports. The report, commissioned by the New York Medical Cannabis Industry Association (NYMCIA), investigated cannabis products purchased from 20 illicit New York City cannabis shops.

In addition to the contaminants demonstrated through lab testing, every product was found to be noncompliant with the state’s proposed branding regulations, which outlaw packaging and product designs that could be considered attractive to children. Some of the tested products even featured images of copyrighted food brands like Rice Krispies, Bloomberg said.

“The report’s findings are deeply troubling and highlight the tremendous risks posed by unscrupulous firms operating above the law. New York has a responsibility to not only protect the health and safety of its residents but also to fulfill the promise of a socially equitable adult-use market. Neither goal can be realized without stricter enforcement against bad actors.” — NYMCIA President Ngiste Abebe, in a statement

New York regulators scrapped the state’s adult-use cannabis testing limits last month for yeast, bacteria, and mold after cultivators expressed concern that the majority of their products wouldn’t pass the strict rules. Meanwhile, officials approved New York‘s first cannabis retail licenses on November 21, prioritizing individuals who were disproportionately affected by prohibition, and regulators have said they intend for legal adult-use sales to launch by 2023.

In September, a group of New York state lawmakers wrote to New York City Mayor Eric Adams asking him to “move swiftly” in clamping down on illegal cannabis sales in the city. The mayor, who is a former New York City Police Department officer, had said in June that he didn’t want to see heavy enforcement against businesses found to be illegally gifting cannabis.

End


Minnesota to Expand Its Medical Cannabis Program

The Minnesota Department of Health has expanded medical cannabis access in the state by adding obsessive-compulsive disorder (OCD) and irritable bowel syndrome (IBS) to the program’s list of qualifying conditions, the Star Tribune reports.

“Research has shown that people who suffer from these conditions can see benefits from using medical cannabis to treat their symptoms.” — Minnesota Department of Health, in a statement

Minnesota‘s medical cannabis program was launched with just nine qualifying conditions but today, there are 19 conditions that qualify patients for access to the program; the additions of OCD and IBS next August will raise that total to 21. Regulators opted against adding opioid use disorder and gastroparesis, a stomach- and digestion-related condition, to the list of qualifying conditions.

Most Minnesotans have had the ability to self-medicate with cannabis since July 1, when the state legalized THC-infused gummies and similar products for adults aged 21 and older. But that hasn’t slowed participation in the state medical cannabis program: more than 39,000 patients are actively enrolled in the program, the report said, up from 29,000 in 2021.

Minnesota Gov. Tim Walz (D) said earlier this month he believes the state was poised to pass full legalization reforms as soon as the next session after Democrats took control of the state Legislature.

End


Young Americans Far More Likely to Smoke Weed Than Cigarettes

A new survey analysis of Gallup’s latest poll data found that young Americans aged 18-29 are more than twice as likely to smoke cannabis than cigarettes, Marijuana Moment reports.

According to the analysis, the past-week smoking rate for cigarettes of Americans aged 18-29 dropped from 15% in 2016-2018 to just 12% in 2019-2022, a new low record, while cannabis consumption rates increased from 21% to 26% — also a new record — for the same group over the same timeframe.

On average, Gallup found that 27% of Americans either smoked cigarettes, used tobacco vapes/e-cigarettes, or smoked cannabis from 2019-2022. And of that segment, 7% of respondents smoked cannabis alone, 9% smoked just cigarettes, and 3% smoked only e-cigarettes.

But while young Americans were the most likely to be using smoking or vaping products of any variety, they were also the most likely to have opted for just using cannabis over tobacco-based products.

Tobacco use rates have consistently dropped for two decades but Americans aged 30-49 are still more likely to consumer cigarettes exclusively (11%) than just cannabis (8%).

The latest Gallup poll found that support for cannabis legalization in the U.S. has maintained a record high of 68%, which the pollster first recorded last year. Another Gallup poll from August, meanwhile, found that nearly half of U.S. adults (49%) had tried cannabis at least once, with 12% identifying as regular consumers.

End


Louisiana First Responders Renew Call for Medical Cannabis Access

First responders in Louisiana are speaking out ahead of a legislative push for cementing their right to access the state’s medical cannabis program, WAFB reports. It is the second attempt in as many years by state Rep. Mandie Landry, a Democrat from New Orleans, to codify the rights of first responders to access the program.

Alex Tony, a former Army medic and current firefighter, called on officials in Louisiana’s Medical Marijuana Task Force to expand medical freedoms for first responders:

“I think that we should be able to make that choice without repercussions. Because I work in a field where psychological issues such as PTSD are not only commonplace but they’re actually presumptive. Meaning at some point in my career I will see something, be involved with something, do something that I will be mentally and emotionally accountable for…for the rest of my life.” — Tony, in a statement

While last year’s bill failed, Rep. Landry said she is willing to renew efforts this year despite each lawmaker being limited to just five legislative proposals this year on account of it being a fiscal year in Louisiana, according to the report.

“I mean we’re always going to try to expand it and clarify issues in the next session,” Landry said. “And I think this group, it’s such a diverse group, they’ve been working really hard. I think they’re going to come up with some good practical suggestions.”

End


Canada Appoints Experts for Cannabis Legalization Law Review

Canada’s government has formally appointed a panel of doctors, academics, and lawyers to conduct its first-ever statutory review of the country’s 2018 Cannabis Act, which federally legalized cannabis for adults, The Canadian Press reports.

The legislative review is coming more than a year later than expected and aims to investigate the health effects of legal cannabis on Canadian citizens and analyze the effects of legalization on Canada’s economy and unregulated cannabis market, which has thrived despite the reforms.

The panel, headed by former foreign deputy minister of justice and deputy attorney general of Canada Morris Rosenberg, now includes four additional experts:

  • Dr. Oyedeji Ayonrinde, an associate professor of psychiatry and psychology at Queen’s University
  • Dr. Patricia Conrod, a clinical psychologist and professor at University of Montreal’s Department of Psychiatry and Addiction
  • Lynda Levesque, a criminal lawyer and member of the Fisher River Cree Nation in Manitoba, Treaty Five territory
  • Dr. Peter Selby, Vice-Chair of Research and Head of the Department of Family and Community’s Division of Mental Health and Addiction

The statutory review in question was mandated by the original legalization bill but, despite consistent outcry from legal cannabis operators about steep taxes and competition with the unregulated marketplace, federal officials were slow to take action.

The Cannabis Act took effect in October 2018; Canada was only the second nation in the world to pass federal adult-use cannabis reforms, after Uruguay.

End


Unlokt Tech: Revolutionizing Cannabis Infusions

The experience of eating edibles has never matched that of smoking a joint or hitting a pipe, largely due to how the body digests cannabinoids, terpenes, and other flavonoids. When edibles are digested, the terpenes are burnt off by acids in the digestive tract and THC is filtered through the liver to create 11-Hydroxy-THC, a byproduct of the metabolic process. This is why the effects when we metabolize THC feel so different from when we inhale it. Unlokt™ is a groundbreaking technology from Day Three Labs that utilizes the concept of first pass metabolism (also known as first pass effect, presystemic metabolism, or elimination). Unlokt packs the cannabinoids and terpenes onto a protein complex that is absorbed directly into the bloodstream, allowing the valuable compounds to bypass the liver. The technology not only has reliable onset time: it is consistent, guaranteeing the same effect for every batch and, most importantly, creates an effect or outcome to match that of inhaling the extract from which it was made. Ganjapreneur connected with Day Three Labs’ CEO Josh Rubin to learn more about what the technology means for the cannabis industry.

“The novel consumer in cannabis is looking for a specific experience or to enhance some part of their life or relieve something. To date, we haven’t been able to consume edibles that achieve those experiences. But now with Unlokt™, we finally have a way of ingesting cannabis and having the desired outcome,” said Day Three Labs CEO Josh Rubin. “We’re providing that precision, we’re providing that predictability, but the most important thing here is we’re actually providing an avenue for all consumers to benefit from cannabis.”

Unlokt™ was developed in an Israeli pharmaceutical research lab before it was introduced to the United States cannabis market. The product is not a nanoemulsion, which can contain harmful ingredients, and it doesn’t work by tricking the body into absorbing cannabinoids – it is a protein complex that takes advantage of a naturally occurring process in the human body. Rather than focus on particle size and emulsion, Day Three Labs packs cannabinoids and terpenes onto the protein complex much like sugar sticks to a raisin in Raisin Bran cereal with only 2 ingredients– cannabis and protein. Before it was implemented, the tech was tested in a tissue culture lab and underwent several animal PK studies. As products made with Unlokt™ debut across the US, the lab and the brands are collecting surveys and anecdotal data, as well.

Denver, Colorado-based Olio was the first brand to release a product formulated with Unlokt™. Their mission is to create products that reflect the garden and as such, prefer to use live rosin. As they shopped for inputs for their live edibles line, many other brands attempted to direct them toward high THC extracts rather than the full spectrum products they desired. Their search eventually led to the partnership with Day Three Labs. The input agnostic technology can be applied to any type of ingestible cannabis products made using rosin, distillate, live resin, and even high-potency tincture. Olio opted to produce a chef-developed live resin gummy including only the finest ingredients, from the live resin input to the fruit de pate. The brand desired an edible that closely matched the effects of inhaling the live resin it was made with, and that is what drew them to Unlokt™.

Steve Morigi, Brand Product and Process Manager at Olio, told Ganjapreneur: “They are, to our knowledge, the only company that can actually do this. They have the studies, they have the labs in Israel, they have the blood tests to show the cannabinoids coming through. We’ve personally just done potency testing and cannabinoid testing, terpene testing on the process pre and post their technology, and we see terpenes being transferred over. We see minor cannabinoids being transferred over and we see strain-specific unique profiles being transferred over.

“It’s just protein and cannabinoids, it’s all-natural and clean,” Morigi said. “But really it’s the experience itself, and that’s why this technology was designed. It was designed to create a far more efficient methodology of delivering cannabinoids directly into circulation. This technology protects the profile of the cannabis entirely and then shuttles that profile directly into circulation. So when we talk about strain specificity that’s what we’re referring to. It’s an entirely different experience than anything out there in the market, and anything to date.”

Day Three Labs has manufacturing labs in Colorado at Olio and their most recently opened site in Costa Mesa, California. They are also scaling an operation in New Mexico. To get started working with Day Three Labs, a brand sends their preferred input to the lab where they take the cannabinoids, terpenes, and desired compounds out and pack them onto protein particles. The exact profile is replicated into every edible. One aspect of this technology that excites Rubin is the ability to take anecdotal data of what cannabis strains can do for patients and hone in on the specific formulations that create the desired experience and effects.

“There’s a real dearth of research around this and very little in terms of precision and predictability. When you’re looking at someone who needs cannabis for a specific indication, activity, or an experience, we have yet to really get there to meet the consumer or the patient where they are. That’s what really motivates me to be pushing for more innovation and R&D for that consumer, so that they have that predictability,” Rubin said.

After the successful launch in Colorado, Unlokt™ technology is making its California debut in Toci Treats from The People’s Ecosystem. Toci Treats are designed for communities of color and will be available in standard 10 mg doses as well as microdoses. CEO Christine De La Rosa expressed gratitude and excitement in a recent interview with Ganjapreneur because people of color will be some of the first with access to this groundbreaking technology. “To create this category of medicine for my communities has always been a dream of mine. And, now that dream is a reality because another company believed in our vision. We believed in them just as much, that’s why this is such a big deal,” De La Rosa said.

Toci Treats are developed by TPE’s Chief Innovation Officer Chef Charleen Caabay in their Santa Rosa facility. After Caabay builds an SOP around a new product, it’s sent to Day Three Labs which identifies Unlokt™’s ideal form for the product and where best to insert the ingredient into the SOP. De La Rosa said, “This is literally the first time that I or anybody in the state of California – and we’re the second people in the United States – will be able to formulate very specifically.”

Being the first to use Unlokt™ in two state markets and crafting products specifically for communities who have been harmed by the war on drugs makes De La Rosa proud. First, for providing medicine for her communities, and second because, “It’s a huge signal to the industry that this is a viable, big, important market.”

And though she voices her pride at being among the first, she doesn’t want TPE to be the last to release products using the Unlokt™ technology. A few more California brands are scheduled to drop new Unlokt™ products in the coming year and it is likely that the technology will continue into new state markets soon.

Rubin is also proud: “We’re providing that precision, we’re providing that predictability, but the most important thing here is we’re actually providing an avenue for all consumers to safely benefit from cannabis as intended,” he said.

To learn more about Day Three Labs and Unlokt™ technology, visit daythreelabs.com.

End


Ohio Lawmakers Consider Medical Cannabis Expansions

Ohio state lawmakers are currently considering a proposal to make medical cannabis available for patients whose conditions “may reasonably be expected to be relieved from medical marijuana,” according to a Cleveland.com report.

The state currently allows medical cannabis as a treatment for 25 conditions including AIDS, Alzheimer’s disease, cancer, Crohn’s disease, epilepsy or another seizure disorder, fibromyalgia, glaucoma, and others. But despite patient frustrations, the Ohio State Medical Board has repeatedly rejected petitions to add certain other conditions including autism spectrum disorder.

Meanwhile, advocates with the Coalition to Regulate Marijuana Like Alcohol are positioned to put an adult-use cannabis legalization proposal before Ohio voters during the November 2023 election.

Following a successful signature-gathering drive by the group, state lawmakers will be forced to consider the advocates’ legalization proposal early next year. If they fail to adopt the reforms — which is the expected outcome — advocates will get four weeks to gather additional signatures to put the issue to voters during the next November election.

Cleveland.com, citing the group’s campaign finance report filed in July, said the campaign has raised $212,500 this year with $150,000 coming from the Marijuana Policy Project cannabis advocacy organization and the remaining funds being donated by several Ohio-based medical cannabis operators. Last year, advocates fundraised $1.3 million towards the effort, according to the report.

End